S
Shinobi Therapeutics
Developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs
About Shinobi Therapeutics
Shinobi Therapeutics is a pioneering biotech company specializing in immune-evasive induced pluripotent stem cell (iPSC) therapies. The company focuses on developing innovative treatments for solid tumor cancers by generating T cells from iPSCs that can evade the immune system. This approach aims to make cell therapies more accessible, reduce costs, and shorten treatment timelines, ultimately benefiting millions of patients.
Read full description
Operating in the biotechnology and healthcare markets, Shinobi Therapeutics serves a diverse range of clients, including top-tier research institutions, healthcare providers, and investors. The business model revolves around partnering with leading institutions to source and advance groundbreaking research in immune-evasive iPSC-derived cell therapies. Revenue is generated through research partnerships, grants, and potential commercialization of their therapies.
Shinobi Therapeutics' technology has been validated in numerous scientific publications and is led by a team of industry leaders with roots in Kyoto and San Francisco. The company's comprehensive immune evasion technology shields against T cells, innate immunity, and antibody-mediated rejection, making their therapies highly effective.
At a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- South San Francisco, United States
- Employees
- 40
- Open positions
- None listed
- Dealroom signal
- 81.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Shinobi Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Aug 2024 | $59M | — | AMED | ↗ |
| SERIES AOther financing | Aug 2024 | $9M | $255M | Mitsubishi UFJ Capital · Yosemite | ↗ |
Growth signals
Latest recorded traffic for Shinobi Therapeutics is 2.1K monthly website visits, up 255.9% over the last three months. Shinobi Therapeutics's team declined 2.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Eight Roads Ventures
F-Prime
D3
AMED
Series A6 investors entered at this stage
EQT Life Sciences
Fast Track Initiative
Astellas Venture
JIC Venture Growth Investments
Mitsubishi UFJ Capital
Yosemite
Other known investors2 additional known investors
Kyoto University
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shinobi Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shinobi Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.